Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Venus Medtech (Hangzhou) HK$1.2 billion H shares placement
Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,500,000 new H shares for an aggregate…
I-Mab $418 million private placement
Davis Polk advised the lead placement agent in connection with I-Mab’s $418 million private placement of 29,133,502 ordinary…
Royalty Pharma $6 billion senior notes offering
Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate…
Nestlé $2.6 billion acquisition of Aimmune Therapeutics
Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with…
American Well strategic partnership with Google Cloud
Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver…
Eli Lilly $1.1 billion notes offering
Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.1…
NN Inc. $825 million sale of life sciences unit to American Securities entities
Davis Polk is advising JP Morgan Securities LLC as financial adviser to NN, Inc. in connection with the $825 million sale of…
Bristol Myers Squibb acquisition of Forbius
Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…
Five Prime Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its…